{"id":6409,"date":"2026-04-29T11:43:38","date_gmt":"2026-04-29T11:43:38","guid":{"rendered":"https:\/\/voxzogopatient-pprd-001.azurewebsites.net\/en-us\/?page_id=6409"},"modified":"2026-06-10T09:57:11","modified_gmt":"2026-06-10T09:57:11","slug":"clinical-results","status":"publish","type":"page","link":"https:\/\/www.voxzogo.com\/en-us\/clinical-results\/","title":{"rendered":"Clinical Results"},"content":{"rendered":"
In a clinical trial<\/span> of children aged 5 to 15 years, the impact of VOXZOGO<\/span> on linear growth was measured over 1 year.<\/p>\n <\/div>\n <\/div>\n <\/div>\n<\/div>\n\n Growth rate before and after 1 year of treatment<\/strong><\/p>\n <\/div>\n\n At year 4, the rate of growth was 1.88 in\/yr.†<\/sup><\/span><\/p>\n \n <\/div>\n <\/div>\n <\/div>\n <\/div>\n<\/div>\n\n *The difference when accounting for group characteristics, including sex and Tanner stage, treatment, baseline<\/span> age, baseline growth rate, and baseline height Z-score.<\/small> Watch Their Stories<\/a><\/p>\n <\/div>\n <\/div>\n <\/div>\n<\/div>\n\n VOXZOGO is approved under accelerated approval based on an improvement in growth rate after 1 year of treatment. Compared to untreated patients in the study, body proportionality<\/span> did not worsen at 1 year.<\/p>\n Because achondroplasia<\/span> is a condition that affects multiple aspects of physical development, additional studies on the impact of VOXZOGO<\/span> over a longer period of time are ongoing, including its effects on final adult height and body proportionality<\/span>.<\/strong><\/p>\n <\/div>\n\n *Visit clinicaltrials.gov for the complete list of the trials’ additional study measures (NCT03583697, NCT03989947, NCT03197766, NCT03424018).<\/small><\/p>\n <\/div>\n <\/div>\n <\/div>\n<\/div>\n\n VOXZOGO can fit into your daily life.<\/p>\n \n \n Your local BioMarin representative can help you find answers.<\/p>\n \n
\t\t\t<\/div>\n\t\t\t
\t\t\t<\/div>\n <\/div>\n <\/figure>\n <\/div>\n <\/div>\n<\/div>\n\nImprovement in linear growth rate over baseline (from when treatment was started) was maintained over 4 years in an ongoing study.<\/span><\/h2>\n
97% of children (58\/60) stayed on VOXZOGO during the first year.‡<\/sup><\/h3>\n
\n†<\/sup>These results are from the long-term follow-up study of the same clinical trial (known as an open-label extension), which did not have a placebo group<\/span>, and caregivers, patients, and doctors were aware that all children were given VOXZOGO.<\/small>
\n‡<\/sup>One child discontinued due to injection pain, and one child discontinued due to fear of needles.<\/small><\/p>\n <\/div>\n <\/div>\n <\/div>\n<\/div>\n\n
\t\t\t<\/div>\n\t\t\t
\t\t\t<\/div>\n <\/div>\n <\/figure>\n\nHear more stories like Annika’s<\/h2>\n
The impact of VOXZOGO continues to be studied<\/h2>\n
\t\t\t<\/div>\n\t\t\t
\t\t\t<\/div>\n <\/div>\n <\/figure>\n\n10+ years of clinical trial experience in achondroplasia<\/h2>\n <\/div>\n <\/div>\n <\/div>\n<\/div>\n\n
Create a routine with your family<\/h3>\n \n
See How <\/a>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n<\/div>\n\n
Looking for more information about VOXZOGO?<\/h2>\n <\/div>\n